Two-year treatment of Alzheimer's disease with eptastigmine

Dementia and Geriatric Cognitive Disorders

Volumn 10, Issue 2, 1999, Pages 139-146

  Imbimbo, Bruno P ^a,b   Verdelli, Giulio ^a   Martelli, Paola ^a   Marchesini, Donata ^a  

^a Medical Department   (Italy)

^b Medical Department   (Italy)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Eptastigmine; Treatment, long term

Indexed keywords

CHOLINESTERASE INHIBITOR; HEPTYLSTIGMINE TARTRATE; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE CONTROL; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERANCE; ELECTROCARDIOGRAM; FEMALE; FUNCTION TEST; HUMAN; LABORATORY TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT;

ACTIVITIES OF DAILY LIVING; ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG MONITORING; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHYSOSTIGMINE;

EID: 0033021454     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000017114     Document Type: Article

References (34)

1. Lamy PP: The role of cholinesterase inhibitors in Alzheimer's disease. CNS Drugs 1994;1: 146-165.
2. Perry EK: The cholinergic hypothesis - Ten years on. Br Med Bull 1986;42:63-69.
3. Giacobini E: Cholinomimetic therapy of Alzheimer disease: Does it slow down deterioration?; in Racagni G, Brunello N, Langer SZ (eds): Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction. Int Acad Biomed Drug Res. Basel, Karger, 1994, vol 7, pp 51-57.
4. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH: Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992; 258:304-307.
5. Mori F, Lai C, Fusi F, Giacobini E: Cholinesterase inhibitors increase secretion of APPs in rat brain cortex. Neuropharmacol Neurotoxicol 1995;6:633-636.
6. Becker RE, Moriearty P, Unni L, Vicari S: Cholinesterase inhibitors as therapy in Alzheimer's disease: Benefit to risk considerations in clinical application; in Becker R, Giacobini E (eds): Alzheimer Disease: From Molecular Biology to Therapy. Boston, Birkhäuser, 1996, pp 257-266.
7. Davis KL: Potential for progress in the therapeutics of Alzheimer's disease: Unanswered questions; in Becker R, Giacobini E (eds): Alzheimer's Disease: From Molecular Biology to Therapy. Boston, Birkhäuser, 1997, pp 399-406.
8. Brufani M, Marta M, Pomponi M: Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia. Eur J Biochem 1986;157:115-120.
9. Imbimbo BP, Licini M, Schettino M, Mosca A, Onelli E, Zecca L, Giustina A: Relationship between pharmacokinetics and pharmacodynamics of eptastigmine in young healthy volunteers. J Clin Pharmacol 1995;35:285-290.
10. Sramek JJ, Block GA, Reines SA, Sawin SF, Barchowsky A, Cutler NR: A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesterase. Life Sci 1995;6: 319-326.
11. Canal N, Imbimbo BP, Eptastigmine Study Group: Relationship between pharmacodynamic activity and cognitive effects of eptastigmine in Alzheimer patients. Clin Pharmacol Ther 1996:60:218-228.
12. Imbimbo BP, Lucca U, Lucchelli F, Alberoni A, Thal LJ, Eptastigmine Study Group: A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer's disease. Alzheimer Dis Assoc Disord 1998;12:313-322.
13. McKhann G, Drachman D, Folstein M, Katzman R, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force on Alzheimer's disease. Neurology 1984;34:939-944.
14. Spinnler H, Tognoni G: Standardizzazione e taratura italiana di test neuropsicologici. Ital J Neurol Sci 1987;6(suppl 8):8-120.
15. Folstein M, Folstein S, McHugh PR: Mini-Mental State: A practical method of grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
16. Reisberg B, Ferris SH, de Leo MJ, Crook T: The Global Deterioration Scale for assessment of primary dementia. Am J Psychiatry 1982; 139:1136-1139.
17. Loeb C, Gandolfo C: Diagnostic evaluation of degenerative and vascular dementia. Stroke 1983;14:399-401.
18. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
19. Rosen WG, Mohs RG, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
20. Lawton MP, Brody EM: Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 1969;9: 179-186.
21. Mosca A, Onelli E, Rosti E, Paleari R, Luzzana M, Imbimbo BP: A patient-side technique for real-time measurement of acetylcholinesterase activity during monitoring of eptastigmine treatment. Ther Drug Monit 1995;17:230-238.
22. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, Scarcey T, Bierer L, Davis KL: A longitudinal study of Alzheimer's disease: Measurement, rate and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396.
23. Green CR, Mohs RC, Schmeidler J, Aryan M, Davis KL: Functional decline in Alzheimer's disease: A longitudinal study. J Am Geriatr Soc 1993;41:654-661.
24. Amberla K, Norberg A, Viitanen M, Winblad B: Long-term treatment with tacrine (THA) in Alzheimer's disease-evaluation of neuropsychological data. Acta Neurol Scand 1993; (suppl 149):55-57.
25. Maltby N, Broe GA, Creasey H, Jorm AF, Christensen H, Brooks WS: Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: Double blind trial. BMJ 1994;308: 879-883.
26. Eagger SA, Richards M, Levy R: Long-term effects of tacrine on Alzheimer's disease: An open study. Int J Geriatr Psychiatry 1994;9: 643-647.
27. Wilcock GK, Scott M, Pearsall T: Long-term use of tacrine. Lancet 1994;343:294.
28. Åhlin A, Junthé T, Hassan M, Nybäck H: One year on tacrine (THA): Clinical and biochemical effects in patients with dementia of the Alzheimer type. Int Psychogeriatr 1995;7:75-83.
29. Solomon PR, Knapp MJ, Gracon SI, Groccia M, Pendlebury WW: Long-term tacrine treatment in patients with Alzheimer's disease. Lancet 1996;348:275-276.
30. Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, Gracon S, Tacrine Study Group: Long-term tacrine (Cognex®) treatment: Effects on nursing home placement and mortality. Neurology 1996;47:166-177.
31. Rogers SL, Friedhoff LT: Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998; 8:67-75.
32. Morris JC, Edland S, Clark C, Galasko D, Koss E, Mohs R, van Belle G, Fillenbaum G, Heyman A: The consortium to establish a registry for Alzheimer's disease (CERAD). IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology 1993;43:2457-2465.
33. Declaration of Helsinki IV, World Medical Association. 41st World Medical Assembly. Hong Kong, September 1989; in Annis GA, Grodin MA (eds): The Nazi Doctors and the Nuremburg Code: Human Right to Human Experimentation. New York, Oxford University Press, 1992, pp 339-342.
34. Eagger SA, Harvey RJ: Clinical heterogeneity: Responders to cholinergic therapy. Alzheimer Dis Assoc Disord 1995;9:37-42.